Trial Profile
A randomized, blinded, placebo and positive-controlled 4-way crossover study to study the effect of multiple doses of apixaban on the QTc interval in healthy subjects.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2015
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Moxifloxacin
- Indications Thromboembolism
- Focus Therapeutic Use
- 23 Nov 2015 New trial record